Renal Denervation Market Assessment 2017-2021

Renal denervation is a minimally invasive catheter based procedure for treatment of resistant hypertension, a condition when at least three hypertensive drugs prove to be ineffective. Although the market experienced appreciable growth in the introductory phase, the method has been proven to be ineffective in treating resistive hypertension. Currently more clinical trials are being conducted which would decide fate of renal denervation market in the future.

Renal denervation technology was initially launched in Europe and Australia. However the study did not prove to be effective in clinical trials conducted in lucrative U.S. market. In 2014, Medtronic announced that the Symplicity trail did not meet primary and secondary end point. Symplicity renal denervation system was launched in April 2010, and is currently available in some parts of Europe, Asia, Africa and Australia. Covidien also took an exit from its clinical trials for OneShot renal denervation program. However, currently Medtronic is conducting clinical trials in U.S., U.K., Germany, Austria, Greece, Japan, and Australia. ReCor has also initiated RADIANCE -HTN study for Paradise System in patients with hypertension in the U.S. U.K., France, Germany and the Netherlands. Success in clinical trials, may fuel the renal denervation market in the future.

Report Sample@ http://www.sa-brc.com/Global-Renal-Denervation-Market-Assessment--Forecast-2017-2021/up57

In 2016, ReCor Medical signed a development and commercialization agreement with Otsuka Holdings, Japan. The agreement gives exclusive rights to commercialization of ReCor Paradise ultrasound based renal denervation system in Japan, China, Korea and other key Asian countries. These events indicate a positive future for renal denervation technology. Improved physician training, refined patient selection and refinement in the novel technology is expected to restore the market growth. Currently there is no treatment available for refractory hypertension patients. Regulatory clearance of renal denervation systems is therefore expected to gain rapid acceptance, considering already existing distribution channels in lucrative markets of Europe and Asia.

Hypertension is expected to cause over 7.5 million mortalities globally which accounts for 12.8% of the total mortalities. An article published by CNN in 2016 mentions that U.S., U.K., Canada and South Korea recorded lowest rate of hypertension globally; while Australia, China, and Russia were among the top countries with high hypertension prevalence. The data also stated that over 400 million hypertension patients were found in India and China alone. However, the level of patients diagnosed with hypertension is low in low- and middle-income countries. This data suggests that there exists enormous scope of renal denervation market development in the Asia countries.

Click For TOC@ http://www.sa-brc.com/Global-Renal-Denervation-Market-Assessment--Forecast-2016-2020/upcomingdetail57

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.